Track topics on Twitter Track topics that are important to you
The global continuous renal replacement therapy CRRT market is growing at the CAGR of 7.69% and will contribute $1290 million till 2022. In regional outlook, market is divided into North America, Europe, Asia Pacific and Rest of the World. Asia Pacific is the fastest growing global continuous renal replacement therapy CRRT market, in terms of revenue in forecast period. Increasing geriatric population, rising healthcare infrastructure are the major reasons which boost the Asia Pacific region's growth in the global continuous renal replacement therapy CRRT market. India and China are the two major countries in Asia Pacific region. Europe is a dominating region in global continuous renal replacement therapy CRRT market. The major reason which enhances the European region is the increasing prevalence of acute kidney injury patients, approval of anticoagulants and CRRT machine for multiple applications. North American region is also a growing market for global continuous renal replacement therapy CRRT market. The reason being the presence of large number of major players in this area, rising prevalence of kidney failure due to rising diabetes, cancer and other chronic diseases. Rest of the world is showing low market growth, but government initiatives regarding kidney diseases therapies is expected to fuel the market growth in this region. Brazil is the major country in terms of revenue generation
Global continuous renal replacement therapy CRRT market is segmented into therapies, products and regional outlook. In therapies segment, the market is divided into SCUF slow continuous ultrafiltration, CVVH continuous venovenous hemofiltration, CVVHD continuous venovenous hemodialysis and CVVHDF continuous venovenous hemodiafiltration. CVVH continuous venovenous hemofiltration was a leader in therapies segment of global continuous renal replacement therapy CRRT market in 2015. The CVVHDF continuous venovenous hemodiafiltration is the fastest growing segment and it is expected to grow even further in the forecast year. In products segment, the market is divided into CRRT systems/ machines, fluid filters, blood purification equipment's, blood line systems, CRRT solutions, CRRT concentrates, dialyzers and other CRRT products. Dialysate dominates the global continuous renal replacement therapy CRRT market in product segment and this dominance is expected to continue in forecast period.
The factors like high cost of these systems, as well as the overall procedure involving continuous renal replacement therapy systems and unfavorable medical reimbursement policies are especially affecting the largescale adoption of continuous renal replacement therapy systems in developing and underdeveloped countries, which hinders the growth of global continuous renal replacement therapy CRRT market. Apart from this, there are many reasons like high cost of continuous renal replacement therapy systems, scarcity of trained staff for handling continuous renal replacement therapy systems, unfavorable medical reimbursement policies in many developing countries and strict rules and regulations in the developed regions are holding back the market.
Some of the major market players are Gambro Baxter, B. Braun Melsungen Ag., Toray Medical Co. Ltd., Fresenius Medical Care Ag., Central Admixture Pharmacy Services, Inc., Asahi Kasei Medical Co., Terumo Bct, Diaverum, Mediates Pharma, Medical Components Inc., etc. Acquisition, mergers and expansions are the key strategies adopted by the market players to sustain in the market.
Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experi...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...